Download PDF
Z Gastroenterol 2015; 53(10): 1194-1200
DOI: 10.1055/s-0041-105701
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Leitlinien für gastroenteropankreatische neuroendokrine Tumoren – was ist neu? Was sollte in die Therapierichtlinien aufgenommen werden?

Guidelines for gastroenteropancreatic neuroendocrine tumors – what is new? What should be incorporated in daily therapeutic decisions?
P. Grabowski
1   Charité, Gastroenterologie, Berlin, Germany
,
D. Hörsch
2   Zentralklinik Bad Berka GmbH, Gastroenterologie, Bad Berka, Germany
› Author Affiliations
Further Information

Publication History

27 March 2015

11 August 2015

Publication Date:
19 October 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Neuroendokrine Neoplasien sind (noch) selten, aber zunehmend. Dies betrifft v. a. die Inzidenz, aber besonders die Prävalenz, da viele Patienten mittlerweile mit der Erkrankung leben (können). Die Europäische Gesellschaft für neuroendokrine Tumoren (European Neuroendocrine Tumor Society, ENETS) hat sich seit ihrer Gründung 2004 sehr um die Standardisierung in Diagnostik und Therapie der neuroendokrinen Tumoren verdient gemacht, und zuletzt 2012 „Consensus Guidelines“ zu gastroenteropankreatischen neuroendokrinen Tumoren veröffentlicht. Wir beziehen uns in unserem Review über neue Entwicklungen in den letzten 2 Jahren, die in eine neue Leitlinie aufgenommen werden sollten, auch auf weitere Fachgesellschaften (NANETS: North American Neuroendocrine Tumor Society; NCCN: National Comprehensive Cancer Network; ESMO: European Society of Medical Oncology), die ebenfalls Leitlinien veröffentlicht haben. Ziel ist es, in einer zusammenfassenden Übersicht einen diagnostisch-therapeutischen Algorithmus zu präsentieren, der im Alltag die aktuellen Empfehlungen umsetzen kann. Weiterhin möchten wir aber auch auf offene Fragen hinweisen, die mit den aktuellen Leitlinien noch nicht zu klären sind und im multidisziplinären Ansatz diskutiert werden sollten.

Abstract

Neuroendocrine neoplasias are seldom, but increasing. This holds true for the incidence but even more for the prevalence, since patients are able to live with their disease for quite a long time. The European Neuroendocrine Tumor Society (ENETS) as well as other societies (NANETS: North American Neuroendocrine Tumor Society; NCCN: National Comprehensive Cancer Network; ESMO: European Society of Medical Oncology) have published diagnostic and therapeutic guidelines that we present in this review. We aim to summarize those actual guidelines in a practice-based diagnostic and therapeutic algorithm, but also wish to point to open questions that have to be discussed in a multidisciplinary approach.

Schlüsselwörter

gastroenteropankreatische Tumoren - therapeutische Strategien - neuroendokrin - Klassifikation - grading-basierter Algorithmus

Key words

gastro-entero-pancreatic tumours - therapeutic strategies - neuroendocrine - classification - grading-based algorithm
 

  • Literatur

  • 1 Modlin IM, Oberg K, Chung DC et al. Review Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 61-72
    CrossrefPubMedGoogle Scholar
  • 2 Hallet J, Law CH, Cukier M et al. Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 2015; 121: 589-597
    CrossrefPubMedGoogle Scholar
  • 3 Bosman FT et al. WHO Classification of Tumours of the Digestive System. Lyon, France: IARC Press; 2010
    PubMedGoogle Scholar
  • 4 Öberg K, Knigge U, Kwekkeboom D et al. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl. 07) vii124-vii130
    CrossrefPubMedGoogle Scholar
  • 5 Williams ED, Sandler M. The Classification of carcinoid tumours. Lancet 1963; 1: 238-239
    PubMedGoogle Scholar
  • 6 Helpap B, Kollermann J. Immunohistochemical analysis of the proliferative activity of neuroendocrine tumors from various organs. Are there indications for a neuroendocrine tumor-carcinoma sequence?. Virchows Arch 2001; 438: 86-91
    CrossrefPubMedGoogle Scholar
  • 7 Scardoni M, Vittoria E, Volante M et al. Mixed Adenoneuroendocrine Carcinomas of the Gastrointestinal Tract: Targeted Next Generation Sequencing Suggests a Monoclonal Origin of the Two Components. Neuroendocrinology 2014; 100: 310-316
    CrossrefPubMedGoogle Scholar
  • 8 Öberg K, Casanovas O, Castaño JP et al. Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. Clin Cancer Res 2013; 19: 2842-2849
    CrossrefPubMedGoogle Scholar
  • 9 Jiao Y, Shi C, Edil BH et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331: 1199-1120
    CrossrefPubMedGoogle Scholar
  • 10 Baum RP, Prasad V, Hommann M et al. Receptor PET/CT imaging of neuroendocrine tumors. Recent Results Cancer Res 2008; 170: 225-242
    PubMedGoogle Scholar
  • 11 Modlin IM, Gustafsson BI, Moss SF et al. Chromogranin a‐biological function and clinical utility in neuroendocrine tumor disease. Ann Surg Oncol 2010; 17: 2427-2443
    CrossrefPubMedGoogle Scholar
  • 12 Modlin I, Drozdov I, Alaimo D et al. A multianalyte pcr blood test outperforms single analyte elisas for neuroendocrine tumor detection. Endocr Relat Cancer 2014; 21: 615-628
    CrossrefPubMedGoogle Scholar
  • 13 Rinke A, Müller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663
    CrossrefPubMedGoogle Scholar
  • 14 Caplin ME, Pavel M, Ćwikła JB et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371: 224-233
    CrossrefPubMedGoogle Scholar
  • 15 Bodei L, Kidd M, Baum RP et al. PRRT: Defining the Paradigm Shift to Achieve Standardization and Individualization. J Nucl Med 2014; 55: 1753-1756
    CrossrefPubMedGoogle Scholar
  • 16 Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523
    CrossrefPubMedGoogle Scholar
  • 17 Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513
    CrossrefPubMedGoogle Scholar
  • 18 Engstrom PF, Lavin PT, Mörtel CG et al. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 1984; 2: 1255-1259
    PubMedGoogle Scholar
  • 19 Strosberg JR, Fine RL, Choi J et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268-275
    CrossrefPubMedGoogle Scholar
  • 20 Moertel C, Kvols L, O’Connel M et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227-232
    CrossrefPubMedGoogle Scholar
  • 21 Smith J, Reidy-Lagunes D. The management of extrapulmonary poorly differentiated (high grade) neuroendocrine carcinomas. Semin Oncol 2013; 40: 100-108
    CrossrefPubMedGoogle Scholar
  • 22 Pavel M, Baudin E, Couvelard A et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95: 157-176
    CrossrefPubMedGoogle Scholar
  • 23 Boudreaux JP, Klimstra DS, Hassan MM et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 2010; 39: 753-766
    CrossrefPubMedGoogle Scholar
  • 24 Schmitt AM, Pavel M, Rudolph T et al. Prognostic and Predictive Roles of MGMT Protein Expression and Promoter Methylation in Sporadic Pancreatic Neuroendocrine Neoplasms. Neuroendocrinology 2014; 100 (01) 35-44
    CrossrefPubMedGoogle Scholar
  • 25 Briest F, Grabowski P. PI3K-AKT-mTOR-Signaling and beyond: the Complex Network in Gastroenteropancreatic Neuroendocrine Neoplasms. Theranostics 2014; 4: 336-365
    CrossrefPubMedGoogle Scholar
  • 26 Pavel ME, Hainsworth JD, Baudin E et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378: 2005-2012
    CrossrefPubMedGoogle Scholar
  • 27 Briest F, Berg E, Freitag H et al. FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors. Oncotarget 2015; 6: 8185-8199
    CrossrefPubMedGoogle Scholar
  • 28 Kwekkeboom DJ, de Herder WW, Kam BL et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130
    CrossrefPubMedGoogle Scholar
  • 29 Kwekkeboom D, Kam B, Van Essen M et al. Somatostatin receptor based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010; 17: R53-R73
    CrossrefPubMedGoogle Scholar
  • 30 Hörsch D, Ezziddin S, Haug A et al. Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry. Recent Results Cancer Res 2013; 194: 457-465
    PubMedGoogle Scholar
  • 31 Sorbye H, Welin S, Langer SW et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013; 24: 152-160
    CrossrefPubMedGoogle Scholar
  • 32 Heetfeld M, Chougnet CN, Olsen IH et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2015; pii ERC-15-0119. [Epub ahead of print]
    PubMedGoogle Scholar
  • 33 Basturk O, Yang Z, Tang LH et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 2015; 39: 683-690
    CrossrefPubMedGoogle Scholar